argenex SE $ARGX Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. reduced its position in argenex SE (NASDAQ:ARGX) by 15.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,189 shares of the company’s stock after selling 31,524 shares during the quarter. Goldman Sachs Group Inc. owned about 0.27% of argenex worth $140,597,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ARGX. AQR Capital Management LLC boosted its holdings in shares of argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after acquiring an additional 122 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth boosted its holdings in shares of argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. boosted its holdings in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARGX has been the subject of several analyst reports. Royal Bank Of Canada cut their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Robert W. Baird upped their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, HC Wainwright upped their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Price Performance

Shares of ARGX stock opened at $891.32 on Monday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market cap of $55.43 billion, a P/E ratio of 39.68, a P/E/G ratio of 1.36 and a beta of 0.47. The business has a fifty day simple moving average of $794.90 and a 200-day simple moving average of $812.60.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. On average, sell-side analysts anticipate that argenex SE will post 26.25 earnings per share for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.